Basket Trials: Accelerating Precision Medicine

By | July 11, 2017

On May 23rd 2017, the cancer research community applauded a landmark accomplishment when for the first time the U.S. Food and Drug Administration (FDA) approved Merck’s pembrolizumabfor use in tumors located in any tissue. While cancers are traditionally organized and treated based on their tissue of origin, tumor sequencing has demonstrated that there are important genetic and molecular similarities between tumors across tissue types. These data prompted researchers to hypothesize that molecularly targeted therapies could be effective independent of a disease’s tissue of origin or histology. This means that drugs..


Click through to the American Association for Cancer Research Cancer Policy Monitor to read the entire piece.

Leave a Reply

Your email address will not be published. Required fields are marked *